コンパニオンアニマル診断市場規模、シェア、動向、2031年までの世界予測

コンパニオンアニマル診断市場は、2026年の35億6,000万米ドルから2031年には54億米ドルへと、年平均成長率（CAGR）8.7%で成長すると予測されています。この成長は、診断技術、予防医療、精密獣医療の未来を形作るいくつかの重要な要因によって牽引されています。

獣医療機関が現在の診断プロセスの精度、スピード、効率性を向上させようとする中で、高度な診断プラットフォームへのニーズが高まっていることが、重要な推進力となっています。伴侶動物医療において、データに基づいた的を絞ったアプローチへのニーズが高まるにつれ、高品質な診断プラットフォームへの需要も増加しています。さらに、予防医療と的を絞った疾患管理への重点移行の必要性も、革新的な診断プラットフォームへの需要の高まりによって後押しされています。この傾向は、AIを活用したデータ分析とクラウドサービスによってさらに強化され、革新的なGMP準拠の診断プラットフォームへの需要につながっています。

調査範囲

本市場調査は、コンパニオンアニマル診断市場を様々なセグメントに分けて分析しています。製品、技術、用途、動物の種類、エンドユーザー、地域別に市場規模と成長可能性を推定することを目的としています。また、主要企業の詳細な競合分析に加え、企業プロファイル、製品および事業内容に関する重要な考察、最近の動向、主要な市場戦略についても詳述しています。

レポート購入のメリット

本レポートは、既存企業はもちろん、新規参入企業や中小企業が市場動向を理解し、より大きな市場シェアを獲得するのに役立ちます。レポートを購入した企業は、以下に概説する5つの戦略のうち、1つ以上を実行に移すことができます。

本レポートは、以下の点について考察を提供します。

コンパニオンアニマル診断市場の成長に影響を与える主要な推進要因（コンパニオンアニマル個体数の増加、ペット保険需要の高まり、動物医療費の増加）、阻害要因（診断機器の高コスト、診断製品に対する厳格な規制と長期にわたる承認プロセス）、機会（迅速検査およびPOC診断用携帯型機器への需要の高まり、AIと機械学習の統合による疾患診断の向上）、そして課題（新興市場における獣医師不足、小規模クリニックにおける導入障壁）の分析。

• 製品開発／イノベーション：コンパニオンアニマル診断市場における今後の技術と製品発売に関する詳細な分析。
• 市場開発：有望な新興市場に関する包括的な情報。本レポートは、地域別の様々なタイプのコンパニオンアニマル診断製品市場を分析します。
• 市場の多様化：コンパニオンアニマル診断市場における製品、未開拓地域、最近の動向、および投資に関する包括的な情報。
• 競合分析：コンパニオンアニマル診断市場における主要企業の市場シェア、戦略、製品、流通ネットワーク、製造能力に関する詳細な分析。

Report Description

The companion animal diagnostics market is expected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, at a CAGR of 8.7%. This growth is driven by several key factors shaping the future of diagnostic technology, preventive care, and precision veterinary medicine.

A key catalyst is the growing need for sophisticated diagnostic platforms as veterinary healthcare organizations seek to improve the accuracy, speed, and efficiency of current diagnostic processes. With the increasing need for a targeted, data-focused approach in companion animal healthcare, demand for high-quality diagnostic platforms is rising. Moreover, the need to shift focus to preventive healthcare and targeted disease management is being fueled by the growing demand for innovative diagnostic platforms. This trend is being augmented by AI-driven data analysis and cloud services, resulting in demand for innovative GMP-compliant diagnostic platforms.

Furthermore, the increasing incidence of chronic, infectious, and age-related diseases in domesticated pets is fueling the need for rapid, efficient diagnostic options. Veterinarians and veterinary labs are increasingly seeking support from specialty diagnostic companies to meet the ever-rising volume of cases through high-throughput testing, molecular testing, and imaging capabilities. The growing momentum toward modernizing the field of vet care, driven by real-time monitoring tools, artificial intelligence-powered predictive analytics, and cloud-based systems, is also fueling the need for new, high-quality diagnostic services.

Advances in technology, including automated analyzers, point-of-care testing, and AI interpretation, are fueling the market by improving test accuracy and turnaround times and expanding testing available in the companion animal space. With more of the companion animal diagnostics space outsourcing expertise in complex animal diagnoses or animal research, these advances also support the continued evolution of the companion animal diagnostics market.

“By technology, molecular diagnostics segment to register the highest CAGR during forecast period.”

The molecular diagnostics segment is expected to see the highest growth in the companion animal diagnostics market due to its ability to deliver accurate results for infectious diseases, genetic disorders, and cancers in pet animals. Improvements in PCR, next-generation sequencing, and liquid biopsy have increased the use of molecular diagnostics, enabling veterinarians to easily test their patients for complex ailments that were previously hard to identify. Additionally, there is a growing need for precision medicine, which requires precise diagnostic methods to provide tailored treatment plans for pets.

“By product, consumables segment accounted for larger market share in 2025.”

In 2025, the consumables segment dominated the companion animal diagnostics market, as reagents, test kits, and diagnostic strips are indispensable components of most tests performed in veterinary labs and animal health centers. Those consumables are used in everyday tests conducted for companion animals, including blood and urinalysis tests. Point-of-care and in-house testing are also widely adopted in the companion animal industry, and these consumables are used on a day-to-day basis. Furthermore, as the need to test animals increases and vet practices move toward preventive testing, there will be a growing demand for consumables, thereby maintaining their dominant market position.

“Asia Pacific to witness highest growth rate during forecast period.”

The Asia Pacific region is expected to witness the fastest growth in the companion animal diagnostics market during the forecast period, driven by the growing number of pet lovers who are spending heavily on their pets. With greater awareness of animal health and higher spending capacity among pet owners, the Asia Pacific market is growing rapidly. The increased use of advanced animal diagnostic equipment, such as point-of-care testing and molecular diagnostics, is meeting the need for high-quality diagnostics at affordable prices. Moreover, advances in animal healthcare infrastructure and animal insurance coverage are driving the animal diagnostics market in the Asia Pacific region.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
• By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
• By Region: North America (45%), Europe (15%), Asia Pacific (25%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By End User: Diagnostic Laboratories (45%), Veterinary Hospitals & Clinics (30%), Veterinary Research Institutes & Universities (15%), and Home Care Settings (10%)
• By Designation: Veterinary Clinicians (47%), Diagnostic Laboratory Directors/Managers (22%), R&D Directors/Product Development Heads (15%), and Others (16%)
• By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the companion animal diagnostics market in various segments. It aims to estimate the market size and growth potential by product, technology, application, animal type, end user, and region. The study also includes an in-depth competitive analysis of the market’s key players, along with their company profiles, key observations on their products and business offerings, recent developments, and key market strategies.

Reasons to Buy Report

The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger share of the market. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

Analysis of key drivers (growth in the companion animal population, rising demand for pet insurance, and increased spending on animal healthcare), restraints (high cost of diagnostic devices, stringent regulations and lengthy approval processes for diagnostic products), opportunities (growing demand for rapid tests and portable instruments for POC diagnostics, integration of AI and ML for enhanced disease diagnosis), and challenges (shortage of veterinary practitioners in emerging markets, barriers to adoption in small clinics) influencing the growth of the companion animal diagnostics market.

• Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the companion animal diagnostics market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of companion animal diagnostic products across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the companion animal diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the companion animal diagnostics market.

Table of Contents

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 STUDY SCOPE 46
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 49
1.3.4 CURRENCY CONSIDERED 49
1.3.5 UNITS CONSIDERED 49
1.4 MARKET STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 50
2 EXECUTIVE SUMMARY 53
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 53
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 54
2.3 DISRUPTIVE TRENDS IN COMPANION ANIMAL DIAGNOSTICS MARKET 55
2.4 HIGH-GROWTH SEGMENTS 56
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 57
3 PREMIUM INSIGHTS 58
3.1 COMPANION ANIMAL DIAGNOSTICS MARKET OVERVIEW 58
3.2 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2025) 59
3.3 COMPANION ANIMAL DIAGNOSTICS MARKET: REGIONAL MIX 60
3.4 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
3.5 COMPANION ANIMAL DIAGNOSTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 62
4 MARKET OVERVIEW 63
4.1 INTRODUCTION 63
4.2 MARKET DYNAMICS 63
4.2.1 DRIVERS 64
4.2.1.1 Growth in companion animal population 64
4.2.1.2 Increasing demand for pet insurance and growth in animal healthcare expenditure 65
4.2.1.3 Growing number of veterinary practitioners 66
4.2.1.4 Increasing prevalence of infectious, parasitic, and chronic diseases in pets 67

4.2.2 RESTRAINTS 68
4.2.2.1 Rising pet care costs 68
4.2.2.2 Limited access to advanced veterinary diagnostic services in developing regions 69
4.2.3 OPPORTUNITIES 69
4.2.3.1 Growing demand for rapid tests and portable instruments for POC diagnostics 69
4.2.3.2 Utilization of AI and ML for enhanced disease diagnosis 70
4.2.4 CHALLENGES 70
4.2.4.1 Low awareness regarding preventive diagnostics among pet owners in price-sensitive markets 70
4.2.4.2 Regulatory and reimbursement limitations in veterinary healthcare diagnostics 71
4.3 UNMET NEEDS & WHITE SPACES 72
4.3.1 UNMET NEEDS IN COMPANION ANIMAL DIAGNOSTICS MARKET 72
4.3.2 WHITE SPACE OPPORTUNITIES 72
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 73
4.4.1 INTERCONNECTED MARKETS 73
4.4.2 CROSS-SECTOR OPPORTUNITIES 74
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74
5 INDUSTRY TRENDS 75
5.1 PORTER’S FIVE FORCES ANALYSIS 75
5.1.1 THREAT OF NEW ENTRANTS 76
5.1.2 THREAT OF SUBSTITUTES 76
5.1.3 BARGAINING POWER OF SUPPLIERS 77
5.1.4 BARGAINING POWER OF BUYERS 77
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.2 MACROECONOMIC INDICATORS 78
5.2.1 INTRODUCTION 78
5.2.2 GDP TRENDS & FORECAST 78
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 80
5.2.4 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY 80
5.3 VALUE CHAIN ANALYSIS 80
5.4 ECOSYSTEM ANALYSIS 82
5.5 PRICING ANALYSIS 83
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 84
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 85
5.5.2.1 Average selling price trend of rapid test kits, by region, 2023−2025 86
5.5.2.2 Average selling price trend of ELISA/immunodiagnostic test kits & reagents, by region, 2023−2025 86
5.5.2.3 Average selling price trend of clinical chemistry reagents, clips & cartridges, by region, 2023−2025 86
5.5.2.4 Average selling price trend of blood glucose strips, by region, 2023−2025 87
5.5.2.5 Average selling price trend of hematology analyzers, by region, 2023−2025 87
5.6 TRADE ANALYSIS 87
5.6.1 TRADE DATA FOR HS CODE 9018 88
5.6.1.1 Import data for HS Code 9018 88
5.6.1.2 Export data for HS Code 9018 88
5.6.2 TRADE DATA FOR HS CODE 3822 89
5.6.2.1 Import data for HS Code 3822 89
5.6.2.2 Export data for HS Code 3822 89
5.7 KEY CONFERENCES & EVENTS, 2026–2027 90
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91
5.9 INVESTMENT & FUNDING SCENARIO 92
5.10 SUCCESS STORIES & REAL-WORLD APPLICATIONS 93
5.10.1 NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION 93
5.10.2 ADOPTION OF AI-ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION 93
5.10.3 DEVELOPMENT OF SNAP 4DX PLUS TEST FOR RAPID VECTOR-BORNE DISEASE DETECTION 94
5.11 IMPACT OF US TARIFFS—COMPANION ANIMAL DIAGNOSTICS MARKET 94
5.11.1 INTRODUCTION 94
5.11.2 KEY TARIFF RATES 96
5.11.3 PRICE IMPACT ANALYSIS 97
5.11.4 IMPACT ON COUNTRIES/REGIONS 98
5.11.5 IMPACT ON END-USE INDUSTRIES 99
5.11.5.1 Veterinary Hospitals & Clinics 99
5.11.5.2 Veterinary Reference Laboratories 100
5.11.5.3 Veterinary Research Institutes & Universities 100
5.11.5.4 Home Care Settings 100
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 101
6.1 KEY EMERGING TECHNOLOGIES 101
6.1.1 AI-ENABLED DIAGNOSTICS 101
6.1.2 PORTABLE INSTRUMENTS FOR POC DIAGNOSTIC SERVICES 101
6.2 COMPLEMENTARY TECHNOLOGIES 102
6.2.1 MICROFLUIDIC DEVICES FOR VETERINARY DIAGNOSTICS 102
6.2.2 CRISPR-BASED MOLECULAR DIAGNOSTICS 103
6.3 ADJACENT TECHNOLOGIES 103
6.3.1 WEARABLE BIOSENSORS & REMOTE MONITORING DEVICES 103
6.3.2 BREATH & SALIVA-BASED DIAGNOSTIC TOOLS 104

6.4 TECHNOLOGY/PRODUCT ROADMAP 104
6.4.1 NEAR TERM (2025–2027) 104
6.4.2 MID-TERM (2028–2030) 105
6.4.3 LONG TERM (2030+) 105
6.5 PATENT ANALYSIS 106
6.5.1 PATENT PUBLICATION TRENDS FOR COMPANION ANIMAL DIAGNOSTIC KITS 106
6.5.2 JURISDICTION & TOP APPLICANT ANALYSIS 107
6.6 FUTURE APPLICATIONS 108
6.6.1 AI-DRIVEN PREDICTIVE DIAGNOSTICS 108
6.6.2 FULLY INTEGRATED DIGITAL VETERINARY ECOSYSTEMS 108
6.6.3 PRECISION & PERSONALIZED VETERINARY DIAGNOSTICS 108
6.6.4 REMOTE & HOME-BASED PET HEALTH MONITORING 108
6.6.5 AUTOMATED HIGH-THROUGHPUT VETERINARY LABORATORIES 108
6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION ANIMAL DIAGNOSTICS MARKET 109
6.7.1 INTRODUCTION 109
6.7.2 MARKET POTENTIAL IN COMPANION ANIMAL DIAGNOSTIC ECOSYSTEM 109
6.7.3 AI USE CASES 110
6.7.4 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET 110
7 REGULATORY LANDSCAPE & SUSTAINABILITY INITIATIVES 112
7.1 REGIONAL REGULATIONS & COMPLIANCE 112
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113
7.1.1.1 North America 113
7.1.1.2 Europe 114
7.1.1.3 Rest of the world 115
7.1.2 INDUSTRY STANDARDS 116
7.2 SUSTAINABILITY INITIATIVES 117
7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS 117
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 117
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 118
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 119
8.1 KEY STAKEHOLDERS & BUYING CRITERIA 119
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 119
8.1.2 BUYING CRITERIA 120
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 121
8.2.1 DECISION-MAKING PROCESS 121
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 122
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 122
8.2.4 MARKET PROFITABILITY 123
9 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT 124
9.1 INTRODUCTION 125
9.2 CONSUMABLES 125
9.2.1 RECURRING NATURE TO BOOST DEMAND 125
9.3 INSTRUMENTS 128
9.3.1 INCREASING DEMAND FOR POC ANALYZERS TO DRIVE MARKET 128
10 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY 131
10.1 INTRODUCTION 132
10.2 IMMUNODIAGNOSTICS 132
10.2.1 LATERAL FLOW ASSAYS 136
10.2.1.1 Rapid tests 138
10.2.1.1.1 Growing prevalence of infectious diseases in pets to fuel demand 138
10.2.1.1.2 Global volume analysis of rapid tests,
2024–2031 (thousand units) 140
10.2.1.2 Strip readers 140
10.2.1.2.1 Advancements in digital and AI-enabled diagnostics to support adoption 140
10.2.1.2.2 Global volume analysis of strip readers,
2024–2031 (thousand units) 142
10.2.2 ELISA TESTS 143
10.2.2.1 Higher sensitivity and specificity of ELISA testing to support market expansion 143
10.2.3 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS 145
10.2.3.1 Rising incidence of allergies and dermatological conditions to fuel market growth 145
10.2.4 IMMUNOASSAY ANALYZERS 147
10.2.4.1 Increasing automation in veterinary diagnostics to drive market growth 147
10.2.5 RADIOIMMUNOASSAYS 149
10.2.5.1 Growing demand for sensitive hormone and endocrine testing to fuel market 149
10.2.6 OTHER IMMUNODIAGNOSTICS PRODUCTS 151
10.3 CLINICAL BIOCHEMISTRY 152
10.3.1 CLINICAL CHEMISTRY ANALYSIS 155
10.3.1.1 Clinical chemistry reagents, clips, and cartridges 157
10.3.1.1.1 Increasing utilization of consumable-based diagnostic workflows to fuel market 157
10.3.1.1.2 Global volume analysis of clinical chemistry reagents, clips, and cartridges, 2024–2031 (thousand units) 159
10.3.1.2 Clinical chemistry analyzers 159
10.3.1.2.1 Growing adoption of in-house veterinary diagnostics to drive analyzer demand 159
10.3.1.2.2 Global volume analysis of clinical chemistry analyzers, 2024–2031 (thousand units) 161
10.3.2 BLOOD GAS & ELECTROLYTE ANALYSIS 162
10.3.2.1 Blood gas and electrolyte reagents, clips, and cartridges 164
10.3.2.1.1 Rising demand for rapid point-of-care consumables to boost market 164
10.3.2.1.2 Global volume analysis of blood gas & electrolyte reagents, clips, and cartridges, 2024–2031 (thousand units) 166
10.3.2.2 Blood gas & electrolyte analyzers 166
10.3.2.2.1 Increasing adoption of compact critical-care analyzers in veterinary clinics to drive market 166
10.3.2.2.2 Global volume analysis of blood gas & electrolyte analyzers, 2024–2031 (thousand units) 168
10.3.3 GLUCOSE MONITORING 169
10.3.3.1 Blood glucose strips 171
10.3.3.1.1 Increasing home-based diabetes management to fuel market 171
10.3.3.1.2 Global volume analysis of blood glucose strips, 2024–2031 (thousand units) 173
10.3.3.2 Glucose monitors 173
10.3.3.2.1 Advancements in portable and continuous glucose monitoring technologies to drive market growth 173
10.3.3.2.2 Global volume analysis of glucose monitors,
2024–2031 (thousand units) 175
10.3.3.3 Urine glucose strips 175
10.3.3.3.1 Cost-effective and non-invasive diabetes screening to propel market 175
10.3.3.3.2 Global volume analysis of urine glucose strips,
2024–2031 (thousand units) 177
10.4 MOLECULAR DIAGNOSTICS 178
10.4.1 PCR TESTS 180
10.4.1.1 Increasing prevalence of infectious diseases in companion animals to support growth 180
10.4.2 MICROARRAYS 183
10.4.2.1 Growing focus on genomic profiling and multiplex testing to drive market 183
10.4.3 NUCLEIC ACID SEQUENCING 184
10.4.3.1 Expanding applications of genomic analysis in veterinary medicine to drive demand 184
10.4.4 OTHER MOLECULAR DIAGNOSTICS PRODUCTS 186
10.5 URINALYSIS 187
10.5.1 URINALYSIS CLIPS & CARTRIDGES 189
10.5.1.1 Growing use of consumable-based urine testing workflows to drive growth 189
10.5.2 URINE ANALYZERS 191
10.5.2.1 Increasing automation in veterinary urinalysis testing to support market growth 191
10.5.3 URINE TEST STRIPS 193
10.5.3.1 Rising demand for rapid and cost-effective urine screening tests to drive market 193
10.6 HEMATOLOGY 195
10.6.1 HEMATOLOGY CARTRIDGES 197
10.6.1.1 Rising use of disposable consumables in automated hematology workflows to fuel demand 197
10.6.2 HEMATOLOGY ANALYZERS 199
10.6.2.1 Growing demand for rapid complete blood count testing to support market growth 199
10.7 OTHER TECHNOLOGIES 201
11 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION 203
11.1 INTRODUCTION 204
11.2 CLINICAL PATHOLOGY 205
11.2.1 INCREASING PREVENTIVE HEALTH SCREENING AND CHRONIC DISEASE MONITORING DRIVES DEMAND 205
11.3 BACTERIOLOGY 207
11.3.1 RISING BACTERIAL INFECTIONS AND ANTIMICROBIAL RESISTANCE CONCERNS BOOST MARKET GROWTH 207
11.4 VIROLOGY 209
11.4.1 GROWING PREVALENCE OF COMPANION ANIMAL VIRAL DISEASES DRIVES GROWTH 209
11.5 PARASITOLOGY 211
11.5.1 INCREASING PARASITIC AND VECTOR-BORNE DISEASE BURDEN SUPPORTS DIAGNOSTIC ADOPTION 211
11.6 OTHER APPLICATIONS 213
12 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE 215
12.1 INTRODUCTION 216
12.2 DOGS 217
12.2.1 RISING PREVALENCE OF CANINE CHRONIC AND VECTOR-BORNE DISEASES DRIVES DIAGNOSTIC DEMAND 217
12.3 CATS 219
12.3.1 GROWING AWARENESS OF FELINE INFECTIOUS AND KIDNEY DISEASES BOOSTS MARKET GROWTH 219
12.4 HORSE 222
12.4.1 INCREASING EQUINE HEALTH MONITORING SUPPORTS DIAGNOSTIC ADOPTION 222
12.5 OTHER COMPANION ANIMALS 224

13 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER 226
13.1 INTRODUCTION 227
13.2 VETERINARY HOSPITALS & CLINICS 227
13.2.1 EXPANDING ADOPTION OF IN-HOUSE POINT-OF-CARE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET 227
13.3 VETERINARY REFERENCE LABORATORIES 229
13.3.1 RISING DEMAND FOR SPECIALIZED AND HIGH-COMPLEXITY VETERINARY DIAGNOSTIC TESTING TO PROPEL MARKET 229
13.4 VETERINARY RESEARCH INSTITUTES & UNIVERSITIES 231
13.4.1 INCREASING RESEARCH FOCUS ON PRECISION AND MOLECULAR VETERINARY DIAGNOSTICS TO SUPPORT GROWTH 231
13.5 HOME CARE SETTINGS 233
13.5.1 GROWING ADOPTION OF AT-HOME PET HEALTH MONITORING AND DIAGNOSTIC TECHNOLOGIES TO BOOST DEMAND 233
14 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION 235
14.1 INTRODUCTION 236
14.2 NORTH AMERICA 238
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 239
14.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 240
14.2.3 US 247
14.2.3.1 Rising preventive pet healthcare spending to drive market 247
14.2.4 CANADA 253
14.2.4.1 Increasing veterinary visits and growing pet population to drive market 253
14.3 EUROPE 260
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 260
14.3.2 EUROPE: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 261
14.3.3 GERMANY 268
14.3.3.1 Large companion animal population and premium veterinary care fuel market growth 268
14.3.4 UK 275
14.3.4.1 High veterinary expenditure and rising chronic pet diseases support diagnostics demand 275
14.3.5 FRANCE 281
14.3.5.1 Willingness of pet owners to spend on pet health to drive market 281
14.3.6 ITALY 287
14.3.6.1 Expansion of veterinary services supports market growth 287
14.3.7 SPAIN 294
14.3.7.1 Growing pet care economy and animal welfare initiatives to fuel market 294
14.3.8 NETHERLANDS 300
14.3.8.1 Developments in veterinary diagnostic products to support market growth 300
14.3.9 SWEDEN 306
14.3.9.1 Growing companion animal care and advanced veterinary infrastructure supporting market growth 306
14.3.10 POLAND 312
14.3.10.1 Expanding veterinary infrastructure and rising pet ownership support market development 312
14.3.11 REST OF EUROPE 318
14.4 ASIA PACIFIC 324
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 325
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 327
14.4.3 CHINA 334
14.4.3.1 Growing urban pet population and rising adoption of pet insurance to propel market 334
14.4.4 JAPAN 340
14.4.4.1 Aging pet population and premium veterinary care to support market growth 340
14.4.5 INDIA 347
14.4.5.1 Expanding pet care industry and rising preventive healthcare awareness fuel market growth 347
14.4.6 AUSTRALIA 353
14.4.6.1 High veterinary expenditure and strong pet insurance penetration to support market growth 353
14.4.7 SOUTH KOREA 359
14.4.7.1 Digital veterinary healthcare expansion to drive market 359
14.4.8 THAILAND 365
14.4.8.1 Urban pet adoption and improving veterinary infrastructure to drive market 365
14.4.9 NEW ZEALAND 371
14.4.9.1 Strong animal welfare culture and preventive care trends support market expansion 371
14.4.10 REST OF ASIA PACIFIC 377
14.5 LATIN AMERICA 383
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 383
14.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 384
14.5.3 BRAZIL 390
14.5.3.1 Massive companion animal population to boost demand 390
14.5.4 MEXICO 396
14.5.4.1 High pet ownership and expanding veterinary services to support market growth 396
14.5.5 ARGENTINA 402
14.5.5.1 Strong pet humanization and preventive healthcare trends support market growth 402
14.5.6 REST OF LATIN AMERICA 408

14.6 MIDDLE EAST & AFRICA 414
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 414
14.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 415
14.6.3 GCC COUNTRIES 421
14.6.3.1 Kingdom of Saudi Arabia (KSA) 427
14.6.3.1.1 Government initiatives to drive market growth 427
14.6.3.2 United Arab Emirates (UAE) 433
14.6.3.2.1 Premium veterinary services and rising pet ownership to drive market 433
14.6.3.3 Rest of GCC Countries 439
14.6.4 REST OF MIDDLE EAST & AFRICA 445
15 COMPETITIVE LANDSCAPE 451
15.1 OVERVIEW 451
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 451
15.3 REVENUE ANALYSIS, 2021−2025 453
15.4 MARKET SHARE ANALYSIS, 2025 454
15.4.1 RANKING OF KEY MARKET PLAYERS 455
15.4.2 US MARKET SHARE ANALYSIS, 2025 457
15.4.3 EUROPE MARKET SHARE ANALYSIS, 2025 458
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 459
15.5.1 STARS 459
15.5.2 EMERGING LEADERS 459
15.5.3 PERVASIVE PLAYERS 459
15.5.4 PARTICIPANTS 459
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 461
15.5.5.1 Company footprint 461
15.5.5.2 Region footprint 462
15.5.5.3 Product footprint 463
15.5.5.4 Technology footprint 464
15.5.5.5 Animal type footprint 465
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 466
15.6.1 PROGRESSIVE COMPANIES 466
15.6.2 RESPONSIVE COMPANIES 466
15.6.3 DYNAMIC COMPANIES 466
15.6.4 STARTING BLOCKS 466
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 468
15.6.5.1 Detailed list of key startups/SMEs 468
15.6.5.2 Competitive benchmarking of key startups 469
15.7 BRAND/PRODUCT COMPARISON 470
15.8 R&D EXPENDITURE OF KEY PLAYERS 471

15.9 COMPANY VALUATION & FINANCIAL METRICS 471
15.9.1 FINANCIAL METRICS 471
15.9.2 COMPANY VALUATION 472
15.10 COMPETITIVE SCENARIO 472
15.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 472
15.10.2 DEALS 473
15.10.3 EXPANSIONS 474
15.10.4 OTHER DEVELOPMENTS 475
16 COMPANY PROFILES 476
16.1 KEY PLAYERS 476
16.1.1 IDEXX LABORATORIES, INC. 476
16.1.1.1 Business overview 476
16.1.1.2 Products offered 477
16.1.1.3 Recent developments 478
16.1.1.3.1 Product launches & enhancements 478
16.1.1.4 MnM view 480
16.1.1.4.1 Key strengths 480
16.1.1.4.2 Strategic choices 480
16.1.1.4.3 Weaknesses & competitive threats 480
16.1.2 ANTECH DIAGNOSTICS, INC. 481
16.1.2.1 Business overview 481
16.1.2.2 Products offered 482
16.1.2.3 Recent developments 482
16.1.2.3.1 Product launches & approvals 482
16.1.2.3.2 Expansions 483
16.1.2.4 MnM view 484
16.1.2.4.1 Key strengths 484
16.1.2.4.2 Strategic choices 484
16.1.2.4.3 Weaknesses & competitive threats 484
16.1.3 ZOETIS SERVICES LLC 485
16.1.3.1 Business overview 485
16.1.3.2 Products offered 486
16.1.3.3 Recent developments 487
16.1.3.3.1 Product launches & enhancements 487
16.1.3.3.2 Deals 488
16.1.3.3.3 Expansions 489
16.1.3.3.4 Other developments 489
16.1.3.4 MnM view 490
16.1.3.4.1 Key strengths 490
16.1.3.4.2 Strategic choices 490
16.1.3.4.3 Weaknesses & competitive threats 490
16.1.4 FUJIFILM CORPORATION 491
16.1.4.1 Business overview 491
16.1.4.2 Products offered 493
16.1.4.3 MnM view 493
16.1.4.3.1 Key strengths 493
16.1.4.3.2 Strategic choices 494
16.1.4.3.3 Weaknesses & competitive threats 494
16.1.5 THERMO FISHER SCIENTIFIC INC. 495
16.1.5.1 Business overview 495
16.1.5.2 Products offered 496
16.1.5.3 MnM view 497
16.1.5.3.1 Key strengths 497
16.1.5.3.2 Strategic choices 497
16.1.5.3.3 Weaknesses & competitive threats 497
16.1.6 BIOMÉRIEUX 498
16.1.6.1 Business overview 498
16.1.6.2 Products offered 499
16.1.6.3 Recent developments 500
16.1.6.3.1 Product launches & approvals 500
16.1.7 BIONOTE 501
16.1.7.1 Business overview 501
16.1.7.2 Products offered 501
16.1.7.3 Recent developments 504
16.1.7.3.1 Product launches & enhancements 504
16.1.7.3.2 Deals 506
16.1.8 VIRBAC 507
16.1.8.1 Business overview 507
16.1.8.2 Products offered 508
16.1.8.3 Recent developments 509
16.1.8.3.1 Deals 509
16.1.8.3.2 Expansions 510
16.1.9 RANDOX LABORATORIES LTD. 511
16.1.9.1 Business overview 511
16.1.9.2 Products offered 511
16.1.9.3 Recent developments 512
16.1.9.3.1 Deals 512
16.1.9.3.2 Expansions 513
16.1.10 INDICAL BIOSCIENCE GMBH 514
16.1.10.1 Business overview 514
16.1.10.2 Products offered 515
16.1.10.3 Recent developments 516
16.1.10.3.1 Product enhancements 516
16.1.11 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD. 517
16.1.11.1 Business overview 517
16.1.11.2 Products offered 517
16.1.11.3 Recent developments 518
16.1.11.3.1 Product launches 518
16.1.11.3.2 Expansions 519
16.1.12 BOULE 520
16.1.12.1 Business overview 520
16.1.12.2 Products offered 521
16.1.12.3 Recent developments 522
16.1.12.3.1 Product launches 522
16.1.12.3.2 Deals 523
16.1.13 INNOVATIVE DIAGNOSTICS 524
16.1.13.1 Business overview 524
16.1.13.2 Products offered 524
16.1.13.3 Recent developments 526
16.1.13.3.1 Other developments 526
16.1.14 MEGACOR DIAGNOSTIK GMBH 527
16.1.14.1 Business overview 527
16.1.14.2 Products offered 527
16.1.14.3 Recent developments 531
16.1.14.3.1 Product launches & enhancements 531
16.1.15 BIOGAL 533
16.1.15.1 Business overview 533
16.1.15.2 Products offered 533
16.2 OTHER PLAYERS 535
16.2.1 GOLD STANDARD DIAGNOSTICS 535
16.2.2 AGROLABO S.P.A. 536
16.2.3 PRECISION BIOSENSOR, INC. 538
16.2.4 SKYLA CORPORATION 539
16.2.5 FASSISI, GMBH 540
16.2.6 WOODLEY EQUIPMENT COMPANY LTD 541
16.2.7 BIOPANDA REAGENTS LTD 543
16.2.8 SKYER, INC. 544
16.2.9 RING BIOTECHNOLOGY CO., LTD. 545
16.2.10 SHENZHEN BIOEASY BIOTECHNOLOGY, INC. 546

17 RESEARCH METHODOLOGY 548
17.1 RESEARCH DATA 548
17.2 RESEARCH METHODOLOGY DESIGN 548
17.2.1 SECONDARY DATA 549
17.2.1.1 Key data from secondary sources 550
17.2.2 PRIMARY DATA 550
17.2.2.1 Key data from primary sources 551
17.2.2.2 Key industry insights 552
17.3 MARKET SIZE ESTIMATION 554
17.3.1 BOTTOM-UP APPROACH 559
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 561
17.5 MARKET SHARE ANALYSIS 562
17.5.1 RESEARCH ASSUMPTIONS 562
17.5.2 GROWTH RATE ASSUMPTIONS 562
17.6 RISK ASSESSMENT 563
17.7 RESEARCH LIMITATIONS 563
17.7.1 METHODOLOGY-RELATED LIMITATIONS 563
17.7.2 SCOPE-RELATED LIMITATIONS 563
18 APPENDIX 564
18.1 DISCUSSION GUIDE 564
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 570
18.3 CUSTOMIZATION OPTIONS 572
18.3.1 PRODUCT ANALYSIS 572
18.3.2 COMPANY INFORMATION 572
18.3.3 GEOGRAPHIC ANALYSIS 572
18.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 572
18.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT 572
18.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 572
18.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS 572
18.4 RELATED REPORTS 573
18.5 AUTHOR DETAILS 574

LIST OF TABLES

TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 49
TABLE 2 NUMBER OF US HOUSEHOLDS THAT OWN A PET IN 2025, BY ANIMAL TYPE (MILLIONS) 64
TABLE 3 AVERAGE PREMIUMS PAID IN US, 2023 VS. 2024 65
TABLE 4 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 5 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 79
TABLE 6 AVERAGE SELLING PRICE TREND OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023–2025 (USD) 84
TABLE 7 AVERAGE SELLING PRICE TREND OF RAPID TEST KITS, BY REGION, 2023−2025 86
TABLE 8 AVERAGE SELLING PRICE TREND OF ELISA/IMMUNODIAGNOSTIC TEST KITS & REAGENTS, BY REGION, 2023−2025 86
TABLE 9 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES, BY REGION, 2023−2025 86
TABLE 10 AVERAGE SELLING PRICE TREND OF BLOOD GLUCOSE STRIPS, BY REGION, 2023−2025 87
TABLE 11 AVERAGE SELLING PRICE TREND OF HEMATOLOGY ANALYZERS, BY REGION, 2023−2025 87
TABLE 12 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 88
TABLE 13 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 88
TABLE 14 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 89
TABLE 15 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 89
TABLE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 90
TABLE 17 CASE STUDY 1: NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION 93
TABLE 18 CASE STUDY 2: ADOPTION OF AI -ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION 93
TABLE 19 CASE STUDY 3: MULTIPLEX ELISA-BASED POC DIAGNOSTIC TEST: TARGETING VECTOR-BORNE DISEASE DETECTION 94
TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES 96
TABLE 21 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR COMPANION ANIMAL DIAGNOSTICS 97
TABLE 22 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 98
TABLE 23 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 98
TABLE 24 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 99
TABLE 25 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 99
TABLE 26 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR PATENTS 107
TABLE 27 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET 111
TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113
TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114
TABLE 30 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115
TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTICS PRODUCTS 119
TABLE 32 KEY BUYING CRITERIA FOR TOP THREE END USERS 121
TABLE 33 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 125
TABLE 34 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC CONSUMABLES 126
TABLE 35 COMPANION ANIMAL DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 36 KEY PLAYERS PROVIDING COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS 128
TABLE 37 COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 130
TABLE 38 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 132
TABLE 39 KEY PLAYERS PROVIDING IMMUNODIAGNOSTIC TECHNOLOGIES 133
TABLE 40 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 134
TABLE 41 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 42 KEY PLAYERS PROVIDING LATERAL FLOW ASSAYS 136
TABLE 43 LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 136
TABLE 44 LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 45 KEY PLAYERS PROVIDING LATERAL FLOW RAPID TESTS 138
TABLE 46 RAPID TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 47 RAPID TESTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 140
TABLE 48 KEY PLAYERS PROVIDING LATERAL FLOW STRIP READERS 141
TABLE 49 STRIP READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 50 STRIP READERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 142
TABLE 51 KEY PLAYERS PROVIDING ELISA TESTS 143
TABLE 52 ELISA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 53 KEY PLAYERS PROVIDING ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS 145
TABLE 54 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 55 KEY PLAYERS PROVIDING IMMUNOASSAY ANALYZERS 147
TABLE 56 IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 57 KEY PLAYERS PROVIDING RADIOIMMUNOASSAYS 149
TABLE 58 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 59 OTHER IMMUNODIAGNOSTICS PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 60 KEY PLAYERS PROVIDING CLINICAL BIOCHEMISTRY PRODUCTS 152
TABLE 61 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 153
TABLE 62 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 63 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYSIS 155
TABLE 64 CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 65 CLINICAL CHEMISTRY ANALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 66 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES 157
TABLE 67 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 68 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 159
TABLE 69 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYZERS 160
TABLE 70 CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 71 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION,
2024–2031 (THOUSAND UNITS) 161
TABLE 72 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYSIS 162
TABLE 73 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 162
TABLE 74 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 75 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS,
AND CARTRIDGES 164
TABLE 76 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 77 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET,
BY REGION, 2024–2031 (THOUSAND UNITS) 166
TABLE 78 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYZERS 167
TABLE 79 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 80 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY REGION,
2024–2031 (THOUSAND UNITS) 168
TABLE 81 KEY PLAYERS PROVIDING GLUCOSE MONITORING 169
TABLE 82 GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 169
TABLE 83 GLUCOSE MONITORING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 84 KEY PLAYERS PROVIDING BLOOD GLUCOSE STRIPS 171
TABLE 85 BLOOD GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 86 BLOOD GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 173
TABLE 87 KEY PLAYERS PROVIDING GLUCOSE MONITORS 174
TABLE 88 GLUCOSE MONITORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 89 GLUCOSE MONITORS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 175
TABLE 90 KEY PLAYERS PROVIDING URINE GLUCOSE STRIPS 176
TABLE 91 URINE GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 92 URINE GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 177
TABLE 93 KEY PLAYERS PROVIDING MOLECULAR DIAGNOSTICS 178
TABLE 94 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 179
TABLE 95 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 96 KEY PLAYERS PROVIDING PCR TESTS 181
TABLE 97 PCR TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 98 MICROARRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 99 NUCLEIC ACID SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 100 OTHER MOLECULAR DIAGNOSTICS PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 101 KEY PLAYERS PROVIDING URINALYSIS PRODUCTS 187
TABLE 102 COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 103 COMPANION ANIMAL URINALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 104 KEY PLAYERS PROVIDING URINALYSIS CLIPS & CARTRIDGES 190
TABLE 105 URINALYSIS CLIPS & CARTRIDGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 190
TABLE 106 KEY PLAYERS PROVIDING URINE ANALYZERS 192
TABLE 107 URINE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 108 KEY PLAYERS PROVIDING URINE TEST STRIPS 193
TABLE 109 URINE TEST STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 110 KEY PLAYERS PROVIDING HEMATOLOGY PRODUCTS 195
TABLE 111 COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 196
TABLE 112 COMPANION ANIMAL HEMATOLOGY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 113 KEY PLAYERS PROVIDING HEMATOLOGY CARTRIDGES 197
TABLE 114 HEMATOLOGY CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 115 KEY PLAYERS PROVIDING HEMATOLOGY ANALYZERS 199
TABLE 116 HEMATOLOGY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 117 KEY PLAYERS PROVIDING OTHER TECHNOLOGIES 201
TABLE 118 OTHER COMPANION ANIMAL DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 119 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 204
TABLE 120 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CLINICAL PATHOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 121 COMPANION ANIMAL DIAGNOSTICS MARKET FOR BACTERIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 122 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VIROLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 210
TABLE 123 COMPANION ANIMAL DIAGNOSTICS MARKET FOR PARASITOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 124 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 125 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 216
TABLE 126 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR DOGS 217
TABLE 127 COMPANION ANIMAL DIAGNOSTICS MARKET FOR DOGS, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 128 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR CATS 220
TABLE 129 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CATS, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 130 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS
FOR HORSES 222
TABLE 131 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HORSES, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 132 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 133 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 227
TABLE 134 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 135 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 136 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 137 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 138 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 236
TABLE 139 COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 237
TABLE 140 NORTH AMERICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 240
TABLE 141 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 142 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 241
TABLE 143 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 241
TABLE 144 NORTH AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 145 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 242
TABLE 146 NORTH AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 147 NORTH AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 148 NORTH AMERICA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 149 NORTH AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 150 NORTH AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 151 NORTH AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 152 NORTH AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 245
TABLE 153 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 245
TABLE 154 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246
TABLE 155 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 246
TABLE 156 US: KEY MACROINDICATORS 247
TABLE 157 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 248
TABLE 158 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 248
TABLE 159 US: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 249
TABLE 160 US: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 161 US: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 250
TABLE 162 US: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 250
TABLE 163 US: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 164 US: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 165 US: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 166 US: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 167 US: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 168 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 252
TABLE 169 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 252
TABLE 170 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 253
TABLE 171 CANADA: KEY MACROINDICATORS 254
TABLE 172 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 254
TABLE 173 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 254
TABLE 174 CANADA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 255
TABLE 175 CANADA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 176 CANADA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 177 CANADA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 178 CANADA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 179 CANADA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 180 CANADA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 257
TABLE 181 CANADA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 182 CANADA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 258
TABLE 183 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 258
TABLE 184 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 259
TABLE 185 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 259
TABLE 186 EUROPE: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 261
TABLE 187 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 262
TABLE 188 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 262
TABLE 189 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 263
TABLE 190 EUROPE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 263
TABLE 191 EUROPE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 192 EUROPE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 264
TABLE 193 EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 264
TABLE 194 EUROPE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 195 EUROPE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 196 EUROPE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 197 EUROPE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 266
TABLE 198 EUROPE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 266
TABLE 199 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 266
TABLE 200 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 267
TABLE 201 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 267
TABLE 202 GERMANY: KEY MACROINDICATORS 268
TABLE 203 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 269
TABLE 204 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 269
TABLE 205 GERMANY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 206 GERMANY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 207 GERMANY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 208 GERMANY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 209 GERMANY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 210 GERMANY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 272
TABLE 211 GERMANY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 212 GERMANY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 272
TABLE 213 GERMANY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 273
TABLE 214 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 273
TABLE 215 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 274
TABLE 216 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 274
TABLE 217 UK: KEY MACROINDICATORS 276
TABLE 218 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 276
TABLE 219 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 276
TABLE 220 UK: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 277
TABLE 221 UK: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 222 UK: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 223 UK: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 224 UK: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 225 UK: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 226 UK: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 227 UK: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 228 UK: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 229 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 280
TABLE 230 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 280
TABLE 231 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 281
TABLE 232 FRANCE: KEY MACROINDICATORS 282
TABLE 233 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 282
TABLE 234 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 282
TABLE 235 FRANCE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 283
TABLE 236 FRANCE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 237 FRANCE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 284
TABLE 238 FRANCE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 284
TABLE 239 FRANCE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 240 FRANCE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 285
TABLE 241 FRANCE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 242 FRANCE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 285
TABLE 243 FRANCE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 286
TABLE 244 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 286
TABLE 245 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 286
TABLE 246 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 287
TABLE 247 ITALY: KEY MACROINDICATORS 288
TABLE 248 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 288
TABLE 249 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 289
TABLE 250 ITALY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 289
TABLE 251 ITALY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 252 ITALY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 290
TABLE 253 ITALY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 290
TABLE 254 ITALY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 255 ITALY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 256 ITALY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 257 ITALY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 292
TABLE 258 ITALY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 292
TABLE 259 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 292
TABLE 260 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 293
TABLE 261 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 293
TABLE 262 SPAIN: KEY MACROINDICATORS 294
TABLE 263 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 295
TABLE 264 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 295
TABLE 265 SPAIN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 296
TABLE 266 SPAIN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 267 SPAIN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 268 SPAIN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 269 SPAIN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 270 SPAIN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 271 SPAIN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 272 SPAIN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 273 SPAIN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 299
TABLE 274 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 299
TABLE 275 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 299
TABLE 276 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 300
TABLE 277 NETHERLANDS: KEY MACROINDICATORS 301
TABLE 278 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 301
TABLE 279 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 301
TABLE 280 NETHERLANDS: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 281 NETHERLANDS: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 302
TABLE 282 NETHERLANDS: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 283 NETHERLANDS: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 284 NETHERLANDS: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 285 NETHERLANDS: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 286 NETHERLANDS: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 287 NETHERLANDS: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 288 NETHERLANDS: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 305
TABLE 289 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 305
TABLE 290 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305
TABLE 291 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 306
TABLE 292 SWEDEN: KEY MACROINDICATORS 307
TABLE 293 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 307
TABLE 294 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 307
TABLE 295 SWEDEN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 308
TABLE 296 SWEDEN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 297 SWEDEN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 309
TABLE 298 SWEDEN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 299 SWEDEN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 309
TABLE 300 SWEDEN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 310
TABLE 301 SWEDEN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 302 SWEDEN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 310
TABLE 303 SWEDEN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 311
TABLE 304 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 311
TABLE 305 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 311
TABLE 306 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 312
TABLE 307 POLAND: KEY MACROINDICATORS 313
TABLE 308 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 313
TABLE 309 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 313
TABLE 310 POLAND: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 314
TABLE 311 POLAND: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 312 POLAND: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 315
TABLE 313 POLAND: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 315
TABLE 314 POLAND: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 315 POLAND: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 316
TABLE 316 POLAND: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 317 POLAND: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 316
TABLE 318 POLAND: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 317
TABLE 319 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 317
TABLE 320 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 317
TABLE 321 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 318
TABLE 322 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 319
TABLE 323 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 319
TABLE 324 REST OF EUROPE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 325 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 320
TABLE 326 REST OF EUROPE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 327 REST OF EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 321
TABLE 328 REST OF EUROPE: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 321
TABLE 329 REST OF EUROPE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 330 REST OF EUROPE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 331 REST OF EUROPE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 322
TABLE 332 REST OF EUROPE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 323
TABLE 333 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 323
TABLE 334 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 323
TABLE 335 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 324
TABLE 336 ASIA PACIFIC: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 327
TABLE 337 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 328
TABLE 338 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 328
TABLE 339 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 329
TABLE 340 ASIA PACIFIC: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 341 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 330
TABLE 342 ASIA PACIFIC: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 343 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 330
TABLE 344 ASIA PACIFIC: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 331
TABLE 345 ASIA PACIFIC: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 331
TABLE 346 ASIA PACIFIC: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 347 ASIA PACIFIC: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 332
TABLE 348 ASIA PACIFIC: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 332
TABLE 349 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 332
TABLE 350 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 333
TABLE 351 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 333
TABLE 352 CHINA: KEY MACROINDICATORS 334
TABLE 353 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 335
TABLE 354 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 335
TABLE 355 CHINA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 336
TABLE 356 CHINA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 357 CHINA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 336
TABLE 358 CHINA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 337
TABLE 359 CHINA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 360 CHINA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 337
TABLE 361 CHINA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 338
TABLE 362 CHINA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 338
TABLE 363 CHINA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 338
TABLE 364 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 339
TABLE 365 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 339
TABLE 366 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 340
TABLE 367 JAPAN: KEY MACROINDICATORS 341
TABLE 368 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 341
TABLE 369 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 342
TABLE 370 JAPAN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 342
TABLE 371 JAPAN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 372 JAPAN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 373 JAPAN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 374 JAPAN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 375 JAPAN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 344
TABLE 376 JAPAN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 344
TABLE 377 JAPAN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 378 JAPAN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 379 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 345
TABLE 380 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 346
TABLE 381 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 346
TABLE 382 INDIA: KEY MACROINDICATORS 347
TABLE 383 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 348
TABLE 384 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 348
TABLE 385 INDIA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 349
TABLE 386 INDIA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 387 INDIA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 388 INDIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 389 INDIA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 390 INDIA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 391 INDIA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 392 INDIA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 393 INDIA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 352
TABLE 394 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 352
TABLE 395 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 352
TABLE 396 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 353
TABLE 397 AUSTRALIA: KEY MACROINDICATORS 354
TABLE 398 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 354
TABLE 399 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 354
TABLE 400 AUSTRALIA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 401 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 355
TABLE 402 AUSTRALIA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 403 AUSTRALIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 356
TABLE 404 AUSTRALIA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 356
TABLE 405 AUSTRALIA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 356
TABLE 406 AUSTRALIA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357
TABLE 407 AUSTRALIA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 408 AUSTRALIA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 409 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 358
TABLE 410 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 358
TABLE 411 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 359
TABLE 412 SOUTH KOREA: KEY MACROINDICATORS 359
TABLE 413 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 360
TABLE 414 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 360
TABLE 415 SOUTH KOREA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 416 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 361
TABLE 417 SOUTH KOREA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 418 SOUTH KOREA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 419 SOUTH KOREA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 420 SOUTH KOREA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 421 SOUTH KOREA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 422 SOUTH KOREA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 423 SOUTH KOREA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 424 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 364
TABLE 425 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 364
TABLE 426 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 365
TABLE 427 THAILAND: KEY MACROINDICATORS 366
TABLE 428 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 366
TABLE 429 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 366
TABLE 430 THAILAND: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 367
TABLE 431 THAILAND: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 432 THAILAND: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 433 THAILAND: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 368
TABLE 434 THAILAND: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 435 THAILAND: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 368
TABLE 436 THAILAND: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 437 THAILAND: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 438 THAILAND: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 439 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 370
TABLE 440 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 370
TABLE 441 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 371
TABLE 442 NEW ZEALAND: KEY MACROINDICATORS 372
TABLE 443 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 372
TABLE 444 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 372
TABLE 445 NEW ZEALAND: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 446 NEW ZEALAND: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 373
TABLE 447 NEW ZEALAND: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 448 NEW ZEALAND: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 449 NEW ZEALAND: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 450 NEW ZEALAND: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 451 NEW ZEALAND: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 452 NEW ZEALAND: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 453 NEW ZEALAND: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 454 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 376
TABLE 455 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 376
TABLE 456 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 377
TABLE 457 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 377
TABLE 458 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 378
TABLE 459 REST OF ASIA PACIFIC: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 460 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 379
TABLE 461 REST OF ASIA PACIFIC: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 462 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 379
TABLE 463 REST OF ASIA PACIFIC: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 464 REST OF ASIA PACIFIC: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 465 REST OF ASIA PACIFIC: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 466 REST OF ASIA PACIFIC: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 467 REST OF ASIA PACIFIC: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 468 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 381
TABLE 469 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 382
TABLE 470 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 382
TABLE 471 LATIN AMERICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 384
TABLE 472 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 384
TABLE 473 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 385
TABLE 474 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 385
TABLE 475 LATIN AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 476 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 477 LATIN AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 478 LATIN AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 479 LATIN AMERICA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 480 LATIN AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 481 LATIN AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 482 LATIN AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 388
TABLE 483 LATIN AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 388
TABLE 484 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 389
TABLE 485 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 389
TABLE 486 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 390
TABLE 487 BRAZIL: KEY MACROINDICATORS 391
TABLE 488 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 391
TABLE 489 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 391
TABLE 490 BRAZIL: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 491 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 492 BRAZIL: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 493 BRAZIL: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 494 BRAZIL: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 495 BRAZIL: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 496 BRAZIL: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 497 BRAZIL: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 394
TABLE 498 BRAZIL: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 394
TABLE 499 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 395
TABLE 500 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 395
TABLE 501 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 396
TABLE 502 MEXICO: KEY MACROINDICATORS 397
TABLE 503 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 397
TABLE 504 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 397
TABLE 505 MEXICO: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 506 MEXICO: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 507 MEXICO: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 508 MEXICO: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 509 MEXICO: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 510 MEXICO: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 511 MEXICO: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 512 MEXICO: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 400
TABLE 513 MEXICO: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 400
TABLE 514 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 401
TABLE 515 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 401
TABLE 516 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 402
TABLE 517 ARGENTINA: KEY MACROINDICATORS 403
TABLE 518 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 403
TABLE 519 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 403
TABLE 520 ARGENTINA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 521 ARGENTINA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 522 ARGENTINA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 523 ARGENTINA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 524 ARGENTINA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 525 ARGENTINA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 526 ARGENTINA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 527 ARGENTINA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 406
TABLE 528 ARGENTINA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 406
TABLE 529 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 407
TABLE 530 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 407
TABLE 531 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 408
TABLE 532 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 408
TABLE 533 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 409
TABLE 534 REST OF LATIN AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 535 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 410
TABLE 536 REST OF LATIN AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 537 REST OF LATIN AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 538 REST OF LATIN AMERICA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 411
TABLE 539 REST OF LATIN AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 540 REST OF LATIN AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 541 REST OF LATIN AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 542 REST OF LATIN AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 543 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 412
TABLE 544 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 413
TABLE 545 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 413
TABLE 546 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 415
TABLE 547 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 415
TABLE 548 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 416
TABLE 549 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 416
TABLE 550 MIDDLE EAST & AFRICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 551 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 417
TABLE 552 MIDDLE EAST & AFRICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 553 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 554 MIDDLE EAST & AFRICA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 418
TABLE 555 MIDDLE EAST & AFRICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 556 MIDDLE EAST & AFRICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 557 MIDDLE EAST & AFRICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 558 MIDDLE EAST & AFRICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 559 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 420
TABLE 560 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 420
TABLE 561 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 421
TABLE 562 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 421
TABLE 563 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 422
TABLE 564 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 422
TABLE 565 GCC COUNTRIES: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 566 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 423
TABLE 567 GCC COUNTRIES: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 568 GCC COUNTRIES: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 424
TABLE 569 GCC COUNTRIES: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 424
TABLE 570 GCC COUNTRIES: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 571 GCC COUNTRIES: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 425
TABLE 572 GCC COUNTRIES: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 573 GCC COUNTRIES: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 574 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 426
TABLE 575 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 426
TABLE 576 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 427
TABLE 577 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 427
TABLE 578 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 428
TABLE 579 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 428
TABLE 580 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 429
TABLE 581 KINGDOM OF SAUDI ARABIA: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 429
TABLE 582 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 583 KINGDOM OF SAUDI ARABIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 584 KINGDOM OF SAUDI ARABIA: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 430
TABLE 585 KINGDOM OF SAUDI ARABIA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 586 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 587 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 588 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL HEMATOLOGY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 589 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 432
TABLE 590 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 432
TABLE 591 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 433
TABLE 592 UNITED ARAB EMIRATES: KEY MACROINDICATORS 434
TABLE 593 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 434
TABLE 594 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 434
TABLE 595 UAE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 435
TABLE 596 UAE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 597 UAE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2024–2031 (USD MILLION) 435
TABLE 598 UAE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 436
TABLE 599 UAE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 600 UAE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 436
TABLE 601 UAE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 602 UAE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 603 UAE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 604 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 438
TABLE 605 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 438
TABLE 606 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 439
TABLE 607 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 439
TABLE 608 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 440
TABLE 609 REST OF GCC COUNTRIES: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 610 REST OF GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY TYPE,
2024–2031 (USD MILLION) 441
TABLE 611 REST OF GCC COUNTRIES: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 612 REST OF GCC COUNTRIES: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 613 REST OF GCC COUNTRIES: GLUCOSE MONITORING MARKET, BY TYPE,
2024–2031 (USD MILLION) 442
TABLE 614 REST OF GCC COUNTRIES: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 442
TABLE 615 REST OF GCC COUNTRIES: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 442
TABLE 616 REST OF GCC COUNTRIES: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 617 REST OF GCC COUNTRIES: COMPANION ANIMAL HEMATOLOGY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 618 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 443
TABLE 619 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 444
TABLE 620 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 444
TABLE 621 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 445
TABLE 622 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 446
TABLE 623 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 624 REST OF MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 625 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 626 REST OF MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYSIS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 627 REST OF MIDDLE EAST & AFRICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 628 REST OF MIDDLE EAST & AFRICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 629 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 630 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL URINALYSIS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 631 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL HEMATOLOGY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 632 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 449
TABLE 633 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 450
TABLE 634 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 450
TABLE 635 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET 451
TABLE 636 COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 455
TABLE 637 US COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 457
TABLE 638 EUROPE COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 458
TABLE 639 COMPANION ANIMAL DIAGNOSTICS MARKET: REGION FOOTPRINT 462
TABLE 640 COMPANION ANIMAL DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 463
TABLE 641 COMPANION ANIMAL DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 464
TABLE 642 COMPANION ANIMAL DIAGNOSTICS MARKET: ANIMAL TYPE FOOTPRINT 465
TABLE 643 COMPANION ANIMAL DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 468
TABLE 644 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPETITIVE
BENCHMARKING OF STARTUPS 469
TABLE 645 COMPANION ANIMAL DIAGNOSTICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MAY 2026 472
TABLE 646 COMPANION ANIMAL DIAGNOSTICS MARKET: DEALS, JANUARY 2022– APRIL 2026 473
TABLE 647 COMPANION ANIMAL DIAGNOSTICS MARKET: EXPANSIONS,
JANUARY 2022– APRIL 2026 474
TABLE 648 COMPANION ANIMAL DIAGNOSTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022– APRIL 2026 475
TABLE 649 IDEXX LABORATORIES, INC.: COMPANY OVERVIEW 476
TABLE 650 IDEXX LABORATORIES, INC.: PRODUCTS OFFERED 477
TABLE 651 IDEXX LABORATORIES, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022−MAY 2026 478
TABLE 652 ANTECH DIAGNOSTICS, INC.: COMPANY OVERVIEW 481
TABLE 653 ANTECH DIAGNOSTICS, INC.: PRODUCTS OFFERED 482
TABLE 654 ANTECH DIAGNOSTICS, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–MAY 2026 482
TABLE 655 ANTECH DIAGNOSTICS, INC.: EXPANSIONS, JANUARY 2022–MAY 2026 483
TABLE 656 ZOETIS SERVICES LLC: COMPANY OVERVIEW 485
TABLE 657 ZOETIS SERVICES LLC: PRODUCTS OFFERED 486
TABLE 658 ZOETIS SERVICES LLC: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022-MAY 2026 487
TABLE 659 ZOETIS SERVICES LLC: DEALS, JANUARY 2022−MAY 2026 488
TABLE 660 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2022−MAY 2026 489
TABLE 661 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2022−MAY 2026 489
TABLE 662 FUJIFILM CORPORATION: COMPANY OVERVIEW 491
TABLE 663 FUJIFILM CORPORATION: PRODUCTS OFFERED 493
TABLE 664 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 495
TABLE 665 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 496
TABLE 666 BIOMÉRIEUX: COMPANY OVERVIEW 498
TABLE 667 BIOMÉRIEUX: PRODUCTS OFFERED 499
TABLE 668 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2026 500
TABLE 669 BIONOTE: COMPANY OVERVIEW 501
TABLE 670 BIONOTE: PRODUCTS OFFERED 501
TABLE 671 BIONOTE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MAY 2026 504
TABLE 672 BIONOTE: DEALS, JANUARY 2022−MAY 2026 506
TABLE 673 VIRBAC: COMPANY OVERVIEW 507
TABLE 674 VIRBAC: PRODUCTS OFFERED 508
TABLE 675 VIRBAC: DEALS, JANUARY 2022–MAY 2026 509
TABLE 676 VIRBAC: EXPANSIONS, JANUARY 2022–MAY 2026 510
TABLE 677 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 511
TABLE 678 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED 511
TABLE 679 RANDOX LABORATORIES LTD.: DEALS, JANUARY 2022−MAY 2026 512
TABLE 680 RANDOX LABORATORIES LTD.: EXPANSIONS, JANUARY 2022–MAY 2026 513
TABLE 681 INDICAL BIOSCIENCE GMBH: COMPANY OVERVIEW 514
TABLE 682 INDICAL BIOSCIENCE GMBH: PRODUCTS OFFERED 515
TABLE 683 INDICAL BIOSCIENCE GMBH: PRODUCT ENHANCEMENTS,
JANUARY 2022−MAY 2026 516
TABLE 684 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.:
COMPANY OVERVIEW 517
TABLE 685 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.:
PRODUCTS OFFERED 517
TABLE 686 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.:
PRODUCT LAUNCHES, JANUARY 2022–MAY 2026 518
TABLE 687 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.:
EXPANSIONS, JANUARY 2022–MAY 2026 519
TABLE 688 BOULE: COMPANY OVERVIEW 520
TABLE 689 BOULE: PRODUCTS OFFERED 521
TABLE 690 BOULE: PRODUCT LAUNCHES, JANUARY 2022–MAY 2026 522
TABLE 691 BOULE: DEALS, JANUARY 2022–MAY 2026 523
TABLE 692 INNOVATIVE DIAGNOSTICS: COMPANY OVERVIEW 524
TABLE 693 INNOVATIVE DIAGNOSTICS: PRODUCTS OFFERED 524
TABLE 694 INNOVATIVE DIAGNOSTICS: OTHER DEVELOPMENTS, JANUARY 2022−MAY 2026 526
TABLE 695 MEGACOR DIAGNOSTIK GMBH: COMPANY OVERVIEW 527
TABLE 696 MEGACOR DIAGNOSTIK GMBH: PRODUCTS OFFERED 527
TABLE 697 MEGACOR DIAGNOSTIK GMBH: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MAY 2026 531
TABLE 698 BIOGAL: COMPANY OVERVIEW 533
TABLE 699 BIOGAL: PRODUCTS OFFERED 533
TABLE 700 GOLD STANDARD DIAGNOSTICS: COMPANY OVERVIEW 535
TABLE 701 AGROLABO S.P.A.: COMPANY OVERVIEW 536
TABLE 702 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW 538
TABLE 703 SKYLA CORPORATION: COMPANY OVERVIEW 539
TABLE 704 FASSISI, GMBH: COMPANY OVERVIEW 540
TABLE 705 WOODLEY EQUIPMENT COMPANY LTD: COMPANY OVERVIEW 541
TABLE 706 BIOPANDA REAGENTS LTD.: COMPANY OVERVIEW 543
TABLE 707 SKYER, INC.: COMPANY OVERVIEW 544
TABLE 708 RING BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 545
TABLE 709 SHENZHEN BIOEASY BIOTECHNOLOGY, INC.: COMPANY OVERVIEW 546
TABLE 710 RISK ASSESSMENT ANALYSIS 563

LIST OF FIGURES

FIGURE 1 COMPANION ANIMAL DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE 47
FIGURE 2 MARKET SCENARIO 53
FIGURE 3 GLOBAL COMPANION ANIMAL DIAGNOSTICS MARKET, 2024–2031 54
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022–2025 54
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF COMPANION ANIMAL
DIAGNOSTICS MARKET 55
FIGURE 6 HIGH-GROWTH SEGMENTS IN COMPANION ANIMAL DIAGNOSTICS MARKET,
2026–2031 56
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN COMPANION ANIMAL DIAGNOSTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 57
FIGURE 8 RISING COMPANION ANIMAL POPULATION TO FUEL MARKET GROWTH 58
FIGURE 9 CONSUMABLES SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE
IN 2025 59
FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING
THE FORECAST PERIOD 60
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 61
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 62
FIGURE 13 COMPANION ANIMAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
FIGURE 14 US: PET EXPENDITURE, DOGS VS CATS, 2024 (USD) 66
FIGURE 15 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 82
FIGURE 17 COMPANION ANIMAL DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 83
FIGURE 18 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS,
BY KEY PLAYER, 2025 (USD) 84
FIGURE 19 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS,
BY REGION, 2025 85
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91
FIGURE 21 COMPANION ANIMAL DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO (2021–2025) 92
FIGURE 22 COMPANION ANIMAL DIAGNOSTIC MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–MAY 2026) 106
FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR COMPANION ANIMAL DIAGNOSTIC KITS PATENTS (JANUARY 2015–MAY 2026) 107
FIGURE 24 AI USE CASES 110
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS 119
FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 120
FIGURE 27 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT 236
FIGURE 28 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT 239
FIGURE 29 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT 326
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN THE COMPANION ANIMAL DIAGNOSTICS MARKET (2021−2025) 453
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS (2025) 454
FIGURE 32 RANKING OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2025 455
FIGURE 33 US: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 457
FIGURE 34 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 458
FIGURE 35 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 460
FIGURE 36 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY FOOTPRINT 461
FIGURE 37 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 467
FIGURE 38 COMPANION ANIMAL DIAGNOSTICS MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS 470
FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022−2025 471
FIGURE 40 EV/EBITDA OF KEY VENDORS 471
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 472
FIGURE 42 IDEXX LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 477
FIGURE 43 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025) 486
FIGURE 44 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2025) 492
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 496
FIGURE 46 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 499
FIGURE 47 VIRBAC: COMPANY SNAPSHOT (2025) 508
FIGURE 48 BOULE: COMPANY SNAPSHOT (2025) 521
FIGURE 49 COMPANION ANIMAL DIAGNOSTICS MARKET: RESEARCH DESIGN 548
FIGURE 50 PRIMARY SOURCES 550
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 552
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE) 553
FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 553
FIGURE 54 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 554
FIGURE 55 REVENUE SHARE ANALYSIS ILLUSTRATION: IDEXX LABORATORIES, INC. 555
FIGURE 56 REVENUE ANALYSIS OF TOP FIVE COMPANIES: COMPANION ANIMAL DIAGNOSTICS MARKET (2025) 555
FIGURE 57 DEMAND-SIDE MARKET ESTIMATION FOR COMPANION ANIMAL
DIAGNOSTICS MARKET 557
FIGURE 58 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COMPANION ANIMAL DIAGNOSTICS MARKET (2026–2031) 558
FIGURE 59 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 558
FIGURE 60 TOP-DOWN APPROACH 559
FIGURE 61 BOTTOM-UP APPROACH 560
FIGURE 62 MARKET DATA TRIANGULATION METHODOLOGY 561

---

---